Tag: LY-Cov555

ACTIV-3 Trial: Monoclonal Antibody for Covid-19

2020 ACTIV-3 TRIAL Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 Multicenter, open-label, randomized comparative trial M Objective: To assess the efficacy of LY-CoV555, a neutralizing monoclonal antibody in hospitalized Covid-19 patients without end-organ damage. Hospitalized patients with Covid-19 who had symptoms 314 for ≤12 days. Excluded from the trial were patients who patients had […]